News

In patients with hepatocellular carcinoma, liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated, but the therapy did not improve rates of overall or progression-free survival over sorafenib.

Mipsagargin, a first-in-class prodrug, showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.

Jordi Bruix, MD, discusses findings of a comparison of modified (m)RECIST and RECIST 1.1 assessments in the RESORCE trial.

In updated results presented at the 2017 International Liver Congress, Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma recurrence following treatment with direct-acting antivirals for hepatitis C virus infection.

The presence of androgen receptor splice variant-7 mRNA in circulating tumor cells was associated with poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies.

Survivors of Ewing sarcoma are left with few long-term complications, according to results from a nonrandomized observational cohort study.

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD) extended progression-free survival in patients with multiple myeloma when used in conjunction with stem cell transplantation compared with RVD alone

Researchers have identified higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion as independent prognostic factors of recurrence in patients treated with sorafenib Nexavar for hepatocellular carcinoma.

Results from a study of microRNA-34a and natural killer cells presented at the 2017 International Liver Congress suggest that microRNA-34a, one of the most documented tumor suppressor microRNAs, could have a role in regulating cytotoxicity and development of the effector NK cells and their target cells.

Veliparib fell short of meeting the primary endpoint in a phase III non–small cell lung cancer trial and a triple-negative breast cancer trial.

Patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.

Beyond hematologic malignancies, adoptive therapy could potentially be effective in solid tumors, such as head and neck cancer, according to early results of a clinical trial.

Patients with chronic lymphocytic leukemia (CLL) who stopped treatment with ibrutinib due to toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation, according to the results of a recently published study.

John A. Snowden, MD, discusses guidelines that offer recommendations for screening and management of myeloma.

Matthew B. Yurgelun, MD, discusses a colorectal cancer study which found nearly 10% of the individuals had an inherited mutation in a cancer susceptibility gene.

Tisagenlecleucel-T has been granted a breakthrough therapy designation by the FDA for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.

Leena Gandhi, MD, PhD, discusses&nbsp;the ongoing phase III ALEX study, which is exploring alectinib as a first-line treatment option for&nbsp;<em>ALK</em>-positive non&ndash;small cell lung cancer.

Mike Janicek, MD,&nbsp;sheds light on why physicians are slow to educate patients on genetic testing, the detection of genes aside from <em>BRCA1/2</em>, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

Atezolizumab (Tecentriq) has been granted an accelerated approval by the FDA as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

An Oncologic Drugs Advisory Committee hearing has been scheduled by the FDA for May 24, 2017, to discuss a new drug application for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab.

Steven J. Katz, MD, discusses a&nbsp;population-based survey which examined&nbsp;the association between patient report of surgical recommendation against contralateral prophylactic mastectomy and to what extent it was discussed with the surgeon.

Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.

Julie R. Brahmer, MD, discusses&nbsp;5-year follow-up data from the CA209-003 study of nivolumab for patients with metastatic non&ndash;small cell lung cancer.

The American Association for Cancer Research has announced Michael A. Caligiuri, MD, will serve as its president and Elizabeth M. Jaffee, MD, will serve as its president-elect for the 2017-2018 term.

The investigational tyrosine kinase inhibitor quizartinib is extremely promising as a monotherapy for patients with <em>FLT3-ITD&ndash;</em>positive relapsed acute myeloid leukemia.

Robert Dreicer, MD, discusses&nbsp;emerging treatments for patients with advanced mCRPC.

Lyndsay J. Willmott, MD, discusses how PARP inhibitor approvals have impacted clinical practice and patient outcomes and quality of life in ovarian cancer.

Sukhmani Padda, MD, discusses&nbsp;the status of ongoing trials participating in the race to the frontline in lung cancer.

Regina Cunningham, PhD, RN, has been appointed chief executive officer of the Hospital of the University of Pennsylvania, Penn Medicine has announced.

Dhanya Nambiar, PhD, discusses&nbsp;he role of galectin-1 in the tumor microenvironment, and the potential for targeting this protein in patients with head and neck cancer.